Page last updated: 2024-12-11

phomopsin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

phomopsin: RN for cpd not in Chemline 7/18/83 [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID6438581
CHEMBL ID446991
CHEBI ID187495
SCHEMBL ID1096541
MeSH IDM0109346

Synonyms (12)

Synonym
64925-80-0
phomopsin a
CHEMBL446991
(e)-2-[[(e)-2-[[(2s)-1-[(3r,4s,7s,10s,11s)-14-chloro-3-ethyl-11,15-dihydroxy-3-methyl-10-(methylamino)-6,9-dioxo-7-prop-1-en-2-yl-2-oxa-5,8-diazabicyclo[10.3.1]hexadeca-1(15),12(16),13-triene-4-carbonyl]-2,5-dihydropyrrole-2-carbonyl]amino]-3-methylpent-2
CHEBI:187495
C19955
phomopsin
nsc 381839
SCHEMBL1096541
(2e)-2-{[(2e)-2-({[(2s)-1-{[(3r,4s,7s,10s,11s)-14-chloro-3-ethyl-11,15-dihydroxy-3-methyl-10-(methylamino)-7-(1-methylethenyl)-6,9-dioxo-2-oxa-5,8-diazabicyclo[10.3.1]hexadeca-1(16),12,14-trien-4-yl]carbonyl}-2,5-dihydro-1h-pyrrol-2-yl]carbonyl}amino)-3-m
DTXSID201017600
Q27461160

Research Excerpts

Overview

Phomopsin A is an anti-mitotic compound from the fungus Phomopsis leptostroniformis. Like maytansine, it is known to compete with vinblastine for binding to tubulin (E. coli)

ExcerptReferenceRelevance
"Phomopsin A is an antimitotic cyclic peptide containing a 13-member ring including an ether linkage. "( Interaction of phomopsin A with porcine brain tubulin. Inhibition of tubulin polymerization and binding at a rhizoxin binding site.
Hashimoto, Y; Iwasaki, S; Kobayashi, H; Li, Y; Tokiwa, Y, 1992
)
2.08
"Phomopsin A is an anti-mitotic compound from the fungus Phomopsis leptostroniformis which is a potent inhibitor of microtubule assembly in vitro; like maytansine, it is known to compete with vinblastine for binding to tubulin (E. "( The interaction of phomopsin A with bovine brain tubulin.
Lacey, E; LudueƱa, RF; Prasad, V; Roach, MC, 1989
)
2.05
"Phomopsin is a mycotoxin known to be carcinogenic."( Influence of phomopsin and ivalin on steroid-hormone binding and growth of MCF-7 human breast cancer cells.
Lewko, WM; van Aswegen, CH; Wittliff, JL, 1985
)
1.36

Toxicity

ExcerptReferenceRelevance
" The same total dose administered at daily rates of 50 or 200 micrograms/kg was more toxic and killed all sheep."( The toxicity of phomopsin for sheep.
Jago, MV; Payne, AL; Peterson, JE; Stewart, PL, 1987
)
0.62
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
oligopeptideA peptide containing a relatively small number of amino acids.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (3)

Assay IDTitleYearJournalArticle
AID1154393Inhibition of sheep brain tubulin assembly by UV-spectrophotometry2014Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12
One-pot synthesis of vinca alkaloids-phomopsin hybrids.
AID412798Inhibition of tubulin polymerisation by UV spectrophotometry2009Journal of medicinal chemistry, Jan-08, Volume: 52, Issue:1
Synthesis and biological evaluation of vinca alkaloids and phomopsin hybrids.
AID412800Inhibition of beta tubulin nucleotide site assessed as inhibition of displacement of cold GDP by [alpha32P]GTP at 20 uM by rapid filtration technique2009Journal of medicinal chemistry, Jan-08, Volume: 52, Issue:1
Synthesis and biological evaluation of vinca alkaloids and phomopsin hybrids.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (53)

TimeframeStudies, This Drug (%)All Drugs %
pre-199013 (24.53)18.7374
1990's15 (28.30)18.2507
2000's10 (18.87)29.6817
2010's11 (20.75)24.3611
2020's4 (7.55)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 30.51

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index30.51 (24.57)
Research Supply Index3.99 (2.92)
Research Growth Index4.60 (4.65)
Search Engine Demand Index34.57 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (30.51)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (3.77%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other51 (96.23%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]